Related Experiment Video
Updated: Feb 28, 2026

Fully Processed Recombinant KRAS4b: Isolating and Characterizing the Farnesylated and Methylated Protein
Published on: January 16, 2020
Impact of KRAS-G12 Mutations on the KRAS-GTP Bound Conformational Dynamics: Structure, Free Energy Barriers and
Zheyao Hu1, Zigan Sha1, Jordi Martí2
1Shanghai Center for Systems Biomedicine, Key Laboratory of Systems Biomedicine (Ministry of Education), Shanghai Jiao Tong University, No. 800 Dongchuan Road, Minhang District, 200240, Shanghai, China.
Abstract:
KRAS is among the most frequently mutated oncogenes in human cancers, with codon 12 representing a dominant hotspot. Despite decades of study, the atomic-level conformational dynamics of KRAS and its G12 mutations remain insufficiently resolved, posing a central barrier to rational drug discovery. Elucidating these dynamics is critical for revealing hidden druggable pockets and enabling the development of mutation-specific inhibitors. Here, we delineate the impact of KRAS G12 mutations on conformational dynamics and GTP binding by performing microsecond-scale, well-tempered metadynamics simulations. This approach yielded precise free energy landscapes that expose mutation-specific alterations to structural states. By introducing biologically meaningful collective variables, including key angles (ϕ) and distances (d1, d2) defining Switch-I, Switch-II, and the P-loop, we identified distinct local and global minima as well as their transition states. Analysis of these transitions reveals how G12 mutations reshape GTP affinity and drive aberrant KRAS activation. We further demonstrated the convergence of the simulations and discussed the physiological relevance of the calculation results in comparison to previously published experimental and theoretical data. Importantly, our analyses uncovered druggable pockets unique to nonpolar G12 mutants, offering novel entry points for inhibitor design. Collectively, this work provides an atomic-level framework for understanding KRAS G12 mutations, establishes transferable collective variables for broader RAS family studies, and opens new avenues for mutation-specific therapeutic development.
Insights
KRAS G12 mutations alter protein dynamics and GTP binding, revealing new druggable pockets for targeted cancer therapies. These findings provide a framework for developing specific inhibitors against KRAS-driven cancers.
Area of Science:
- Molecular Biology
- Computational Chemistry
- Oncology
Background:
- KRAS is a frequently mutated oncogene in human cancers, particularly at codon 12.
- Understanding KRAS G12 mutation dynamics is crucial for developing targeted cancer drugs.
- Current knowledge of KRAS atomic-level dynamics and mutation effects is limited.
Purpose of the Study:
- To investigate the impact of KRAS G12 mutations on protein dynamics and GTP binding.
- To identify mutation-specific conformational changes and druggable pockets.
- To provide an atomic-level framework for KRAS G12 mutation research and drug development.
Main Methods:
- Microsecond-scale, well-tempered metadynamics simulations.
- Analysis of free energy landscapes using collective variables (angles, distances) for Switch-I, Switch-II, and P-loop.
- Comparison of simulation results with experimental and theoretical data.
Main Results:
- Identified mutation-specific alterations in KRAS structural states and free energy landscapes.
- Revealed how G12 mutations affect GTP binding affinity and KRAS activation.
- Uncovered unique druggable pockets in nonpolar G12 KRAS mutants.
Conclusions:
- KRAS G12 mutations significantly reshape protein dynamics and GTP binding.
- The study provides a detailed atomic-level understanding of KRAS G12 mutations.
- Identified novel therapeutic targets and strategies for mutation-specific KRAS inhibitors.
More Related Videos
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
The Ras Gene
Ras is a...
GTPases and their Regulation
Large G-proteins,...
GTPases and their Regulation
MAPK Signaling Cascades
GPCR Desensitization